Prostate Cancer | Specialty

The prostate cancer condition center is a comprehensive resource for clinical news and expert insights on prostate cancer. Read more at OncLive.

The OncFive: Top Oncology Articles for the Week of 11/24

November 30th 2024

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Dr Tawagi on the Growing Role of Precision Medicine in Prostate Cancer

November 27th 2024

Karine Tawagi, MD, discusses the use of targeted therapies in the management of metastatic prostate cancer.

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

November 25th 2024

Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

November 21st 2024

The FDA has accepted a sNDA for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents

November 21st 2024

Sandy Srinivas, MD, details updates from 2024 in the kidney and prostate cancer NCCN guidelines and agents/trials to look forward to in 2025.

The OncFive: Top Oncology Articles for the Week of 11/10

November 16th 2024

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

177Lu-PSMA-I&T Meets rPFS End Point in PSMA+ mCRPC

November 13th 2024

177Lu-PSMA-I&T improved radiographic progression-free survival vs hormonal therapy in PSMA-positive metastatic castration-resistant prostate cancer.

Dr Garrot on Lutetium Lu 177 Vipivotide Tetraxetan in Older Patients with MCRPC

November 7th 2024

Louis Crain Garrot, MD, discusses the role of lutetium Lu 177 in older patients with metastatic castration-resistant prostate cancer.

ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC

November 1st 2024

The phase 2 study of masofaniten plus enzalutamide in mCRPC naive to second-generation antiandrogen therapy has been discontinued.

Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients

October 31st 2024

Results of the TALAPRO-2 trial showed that a novel prostate cancer therapy has a higher overall survival rate compared to the standard of care drug alone.

Patients Characteristics, Sequencing Considerations Are Vital in Prostate Cancer Management

October 30th 2024

Bradley C. Carthon, MD, PhD, discusses recent data and the evolving treatment landscape in prostate cancer.

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

October 30th 2024

The FDA has received an NDA seeking the approval of a 3-month formulation of leuprolide mesylate for advanced prostate cancer.

Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future

October 30th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Dr Carthon on Darolutamide Plus ADT in mHSPC

October 29th 2024

Bradley C. Carthon, MD, PhD, discusses treatment with darolutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer

Dr Saad on the Safety Profile of Darolutamide Plus ADT in mHSPC

October 25th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the safety findings from the phase 3 ARANOTE trial investigating darolutamide plus ADT in patients with mHSPC.

Dr Yuh on the Role of Genetic Factors in Risk Stratification for Prostate Cancer

October 24th 2024

Bertram Yuh, MD, MISM, MSHCPM, discusses the role of genetic factors, such as BRCA mutations, in the risk stratification of patients with prostate cancer.

177Lu-PNT2002 Boosts rPFS in PSMA+ mCRPC Following ARPI Progression

October 23rd 2024

177Lu-PNT2002 improved radiographic progression-free survival in PSMA-positive mCRPC after progression on an ARPI.

ONCT-534 Reduces PSA Levels, Is Tolerable in Relapsed/Refractory mCRPC

October 22nd 2024

ONCT-534 reduced prostate-specific antigen levels in patients with relapsed/refractory metastatic castration-resistant prostate cancer.

ARANOTE Data Highlight Darolutamide Plus ADT as a Potential Chemo-Free Option in mHSPC

October 17th 2024

Fred Saad, MD, FRCS, discusses efficacy and safety data for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

Cabozantinib Plus Atezolizumab Fails to Improve OS Over Subsequent Novel Hormonal Therapy in mCRPC

October 17th 2024

Cabozantinib plus atezolizumab did not produce superior OS outcomes vs a second novel hormonal therapy in metastatic castration-resistant prostate cancer.